Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
暂无分享,去创建一个
D. Mccrory | R. Barst | D. Badesch | G. Simonneau | V. McLaughlin | S. Abman | G. Ahearn
[1] R. Benza,et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.
[2] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[3] A. Negassa,et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. , 2005, European heart journal.
[4] Steven H Abman,et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[5] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[6] M. Humbert,et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol , 2005, Thorax.
[7] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.
[8] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[9] D. Mccrory,et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[10] D. Mccrory,et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[11] L. Rubin. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[12] D. Mccrory,et al. Methodology and grading for pulmonary hypertension evidence review and guideline development. , 2004, Chest.
[13] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[14] D. Mccrory,et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[15] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[16] M. Herink. Über primäre pulmonale Hypertonie im Kindesalter , 2004, Zeitschrift für Kinderheilkunde.
[17] W. Krause,et al. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man , 2004, European Journal of Clinical Pharmacology.
[18] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[19] M. Humbert,et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.
[20] W. Seeger,et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.
[21] R. Barst,et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.
[22] G. Funk,et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.
[23] S. Rich,et al. Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.
[24] R. Hetzer,et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. , 2003, European heart journal.
[25] V. Mathew,et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. , 2003, Indian heart journal.
[26] A. Branzi,et al. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension , 2002, European Respiratory Journal.
[27] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[28] N. Pereira,et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. , 2002, The American journal of cardiology.
[29] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[30] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[31] C. Narasimhan,et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.
[32] S. Rich,et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.
[33] S. Archer,et al. Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .
[34] G. Simonneau,et al. New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[35] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[36] W. Seeger,et al. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.
[37] R. Barst,et al. Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[38] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[39] G. Simonneau,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆ , 2002 .
[40] G. Verleden,et al. Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. , 2002, Transplantation.
[41] R. Speich,et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.
[42] B. Cairns,et al. Inhaled Nitric Oxide for Primary Pulmonary Hypertension in Pregnancy , 2001, Obstetrics and gynecology.
[43] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.
[44] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[45] R. Barst,et al. Pulmonary vasoreactivity in PPH. , 2001, Journal of the American College of Cardiology.
[46] G. Sybrecht,et al. Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.
[47] M. Humbert,et al. Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.
[48] B. Winters,et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[49] L. Monnery,et al. Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. , 2001, British journal of anaesthesia.
[50] N. Morrell,et al. Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.
[51] F. Narducci,et al. Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[52] G. Olson,et al. Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy. , 2001, Chest.
[53] M. Uematsu,et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.
[54] K. Bremme,et al. Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension , 2001, Acta anaesthesiologica Scandinavica.
[55] A. Loeckinger,et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. , 2001, American journal of respiratory and critical care medicine.
[56] W. Seeger,et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. , 2001, The European respiratory journal.
[57] H. Farber,et al. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.
[58] I. Khan,et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.
[59] P. Kuo,et al. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. , 2000, Transplantation.
[60] W. Hurford,et al. Effects of Intravenous Zaprinast and Inhaled Nitric Oxide on Pulmonary Hemodynamics and Gas Exchange in an Ovine Model of Acute Respiratory Distress Syndrome , 2000, Anesthesiology.
[61] W. Vogel,et al. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. , 2000, Wiener klinische Wochenschrift.
[62] B. Besse,et al. Oral Beraprost Sodium, a Prostaglandin I2 Analogue, for Intermittent Claudication A Double-Blind, Randomized, Multicenter Controlled Trial , 2000 .
[63] B. Besse,et al. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. , 2000, Circulation.
[64] M. Hoeper,et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.
[65] C. Pedersen,et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. , 2000, The European respiratory journal.
[66] W. Seeger,et al. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.
[67] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[68] R. Aubry,et al. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report. , 2000, The Journal of reproductive medicine.
[69] W. Seeger,et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.
[70] J. Pearl,et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. , 1999, The Annals of thoracic surgery.
[71] S. Rich,et al. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.
[72] M. Vayssairat. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. , 1999, The Journal of rheumatology.
[73] Y. Okano,et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.
[74] R. Wiesner,et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.
[75] A. Atz,et al. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. , 1999, Anesthesiology.
[76] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[77] A. Chaouat,et al. Improvement of pulmonary hypertension after liver transplantation. , 1999, Chest.
[78] S. Rich,et al. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.
[79] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.
[80] M. Landzberg,et al. Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension. , 1999, American journal of obstetrics and gynecology.
[81] G. Maislin,et al. Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.
[82] P. Huang,et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.
[83] W R Clarke,et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.
[84] K.,et al. Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension. , 1998, British journal of anaesthesia.
[85] S. Rybalkin,et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.
[86] D. Ivy,et al. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. , 1998, The Journal of pediatrics.
[87] L. Rubin,et al. Primary pulmonary hypertension , 1998, The Lancet.
[88] M. Humbert,et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.
[89] D. Ivy,et al. Hemodynamic effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, Chest.
[90] J. W. Miller,et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.
[91] O. Hess,et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. , 1998, Journal of the American College of Cardiology.
[92] W R Clarke,et al. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. , 1998, American journal of respiratory and critical care medicine.
[93] D. Ivy,et al. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. , 1998, The Journal of thoracic and cardiovascular surgery.
[94] M. Maclean. Endothelin-1: a mediator of pulmonary hypertension? , 1998, Pulmonary pharmacology & therapeutics.
[95] M. Humbert,et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.
[96] C. Howell,et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.
[97] R. D. Rudic,et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. , 1998, The Journal of clinical investigation.
[98] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[99] T. Higenbottam,et al. Primary and secondary pulmonary hypertension , 1998 .
[100] E. Block,et al. A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”* , 1997, The Journal of Biological Chemistry.
[101] N. Hill,et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. , 1997, Journal of applied physiology.
[102] G. Klintmalm,et al. Severe pulmonary hypertension in liver transplant candidates. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[103] B. Brundage,et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.
[104] K. Maruyama,et al. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. , 1997, Circulation.
[105] R. Dixon,et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. , 1997, Journal of Medicinal Chemistry.
[106] Y. Okano,et al. Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.
[107] A. Halbower,et al. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. , 1997, The American journal of physiology.
[108] J P Cooke,et al. Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.
[109] R. Speich,et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.
[110] C. Howell,et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.
[111] Cook,et al. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. , 1997, The New England journal of medicine.
[112] M. Petch,et al. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.
[113] J Benichou,et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.
[114] T. Saji,et al. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. , 1996, The American journal of cardiology.
[115] W. Auger,et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.
[116] D. Schraufnagel,et al. Structural and pathologic changes in the lung vasculature in chronic liver disease. , 1996, Clinics in chest medicine.
[117] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[118] P. Ganz,et al. Atherosclerosis: risk factors and the vascular endothelium. , 1996, American heart journal.
[119] S. Okazaki,et al. Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium. , 1996, General pharmacology.
[120] S. Nishio,et al. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. , 1996, Journal of cardiovascular pharmacology.
[121] K. Morris,et al. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. , 1996, The Journal of clinical investigation.
[122] S. Oparil,et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. , 1995, Journal of applied physiology.
[123] N. Voelkel,et al. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.
[124] J. Russell,et al. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. , 1995, American journal of respiratory and critical care medicine.
[125] S. Das,et al. Nitric oxide: its identity and role in blood pressure control. , 1995, Life sciences.
[126] D. Stewart,et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. , 1995, Circulation.
[127] R. Cohen,et al. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. , 1995, Progress in cardiovascular diseases.
[128] J. Loscalzo,et al. Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.
[129] J. Canty,et al. Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide. , 1995, International journal of cardiology.
[130] P. Vanhoutte,et al. Endothelium-dependent responses in hypertension. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.
[131] D. Harrison,et al. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. , 1995, The Journal of clinical investigation.
[132] A. Quyyumi,et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. , 1995, Circulation.
[133] H. Kiss,et al. Primary pulmonary hypertenson in pregnancy: A case report , 1995 .
[134] G. Pieper,et al. Amelioration by L‐Arginine of a Dysfunctional Arginine/Nitric Oxide Pathway in Diabetic Endothelium , 1995, Journal of cardiovascular pharmacology.
[135] D. Mitchell,et al. AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. , 1995, Thorax.
[136] J. Sandoval,et al. Primary pulmonary hypertension in children: clinical characterization and survival. , 1995, Journal of the American College of Cardiology.
[137] A. Denjean,et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.
[138] P. Bruni,et al. Identification of a specific transport system for L-arginine in human platelets. , 1995, Biochemical and biophysical research communications.
[139] C. Bose,et al. Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. , 1995, Biology of the neonate.
[140] T. Rector,et al. Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. , 1994, The American journal of cardiology.
[141] K. Yamane. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. , 1994, Internal medicine.
[142] R. Barst,et al. Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.
[143] R. Cramb,et al. Pulmonary hypertension and pregnancy: a series of eight cases , 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[144] W. Paulus. Endothelial control of vascular and myocardial function in heart failure , 1994, Cardiovascular drugs and therapy.
[145] S. Hohnloser,et al. Elevated High-Density Lipoprotein Levels Ameliorate Abnormal Vasoconstriction in Early Atherosclerosis , 2005 .
[146] G. Simonneau,et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.
[147] J. Stamler,et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. , 1994, Circulation.
[148] K. Ivanova,et al. Soluble Guanylyl Cyclase and Platelet Function a , 1994, Annals of the New York Academy of Sciences.
[149] W. Clarke,et al. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. , 1994, Pulmonary pharmacology.
[150] D. Hayoz,et al. Endothelial dysfunction in chronic heart failure. Experimental and clinical studies. , 1994, Arzneimittel-Forschung.
[151] L. Raij,et al. Glomerular thrombosis in pregnancy: role of the L-arginine-nitric oxide pathway. , 1994, Kidney international.
[152] W. Hurford,et al. Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. , 1994, Chest.
[153] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[154] K. Żmudka,et al. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. , 1994, Wiener klinische Wochenschrift.
[155] J. Kellum,et al. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. , 1994, Life sciences.
[156] R. Trifiletti,et al. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.
[157] W. Vogel,et al. Effects of repeated stress on plasma arginine levels in young and old rats , 1993, Physiology & Behavior.
[158] D. Hayoz,et al. Endothelial function in congestive heart failure. , 1993, American heart journal.
[159] T. Evans,et al. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. , 1993, British journal of clinical pharmacology.
[160] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[161] J. Coligan,et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.
[162] T. McMahon,et al. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. , 1993, Journal of applied physiology.
[163] T Takishima,et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. , 1993, Japanese circulation journal.
[164] B. Groves,et al. CORRELATION OF ACUTE PROSTACYCLIN RESPONSE IN PRIMARY (UNEXPLAINED) PULMONARY HYPERTENSION WITH EFFICACY OF TREATMENT WITH CALCIUM CHANNEL BLOCKERS AND SURVIVAL , 1993 .
[165] T. Gasior,et al. Pulmonary hypertension and liver transplantation. , 1993, Anesthesiology.
[166] S. Moncada,et al. The biological and pharmacological role of nitric oxide in platelet function. , 1993, Advances in experimental medicine and biology.
[167] T. Lüscher,et al. Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.
[168] T. Lüscher,et al. Endothelial dysfunction in coronary artery disease. , 1993, Annual review of medicine.
[169] S. Soifer,et al. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. , 1993, The American journal of physiology.
[170] E. Shaffer,et al. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn , 1992, The Lancet.
[171] J. Cooke,et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.
[172] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[173] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[174] H. Palevsky,et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.
[175] S. Rich,et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. , 1992, Journal of the American College of Cardiology.
[176] J. Stamler,et al. Endothelium‐Derived Relaxing Factor Modulates the Atherothrombogenic Effects of Homocysteine , 1992, Journal of cardiovascular pharmacology.
[177] E. Bassenge. Clinical relevance of endothelium-derived relaxing factor (EDRF). , 1992, British journal of clinical pharmacology.
[178] T. Lüscher,et al. Endothelium‐Dependent Regulation of Resistance Arteries: Alterations with Aging and Hypertension , 1992, Journal of cardiovascular pharmacology.
[179] H. Drexler,et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.
[180] T. Higenbottam,et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.
[181] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[182] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[183] J. Cooke,et al. Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.
[184] E. Sybertz,et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. , 1991, Advances in experimental medicine and biology.
[185] J. Cooke,et al. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. , 1990, Circulation research.
[186] S. Abman,et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.
[187] J. Beavo,et al. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. , 1990, Trends in pharmacological sciences.
[188] B. Groves,et al. 26. Pulmonary Hypertension Associated with Hepatic Cirrhosis , 1990 .
[189] J. Bultinck,et al. Pulmonary fat embolism presenting as chronic respiratory failure. , 1989, The European respiratory journal.
[190] W. Edwards,et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. , 1987, Journal of the American College of Cardiology.
[191] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[192] S. Jamieson,et al. Primary pulmonary hypertension and pregnancy. , 1986, Chest.
[193] W. J. Visek,et al. Arginine needs, physiological state and usual diets. A reevaluation. , 1986, The Journal of nutrition.
[194] L. Zieve. Conditional deficiencies of ornithine or arginine. , 1986, Journal of the American College of Nutrition.
[195] G. Guyatt,et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.
[196] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.
[197] R. San Antonio,et al. Laennec's cirrhosis and primary pulmonary hypertension. , 1980, American heart journal.
[198] P. Ogburn,et al. Levels of free fatty acids and arachidonic acid in pregnancy and labor. , 1980, The Journal of laboratory and clinical medicine.
[199] S. Sothy,et al. Carbohydrate and lipid metabolism during human labor: free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. , 1976, Metabolism: clinical and experimental.
[200] A. Fishman. Dietary Pulmonary Hypertension , 1974, Circulation research.
[201] C. Wagenvoort,et al. Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases , 1970 .
[202] G. Kerr. The Free Amino Acids of Serum During Development of Macaca mulatto II. During Pregnancy and Fetal Life , 1968, Pediatric Research.
[203] G. H. Nelson,et al. Alterations of plasma free fatty acids and glucose during labor. , 1967, American journal of obstetrics and gynecology.
[204] H. Mendelow,et al. CONCURRENT "ACTIVE JUVENILE CIRRHOSIS" AND "PRIMARY PULMONARY HYPERTENSION". , 1965, The American journal of medicine.
[205] L. Dunn,et al. PRIMARY PULMONARY HYPERTENSION IN PREGNANCY. , 1964, Obstetrical & gynecological survey.
[206] R. Naeye. "Primary" Pulmonary Hypertension with Coexisting Portal Hypertension: A Retrospective Study of Six Cases , 1960, Circulation.
[207] E. Craige,et al. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. , 1951, A.M.A. archives of pathology.